Aura Biosciences Inc (AURA) - Total Liabilities
Based on the latest financial reports, Aura Biosciences Inc (AURA) has total liabilities worth $30.43 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Aura Biosciences Inc to evaluate the company's liquid asset resilience ratio.
Aura Biosciences Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Aura Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Aura Biosciences Inc.
Aura Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Aura Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anhui Korrun Co Ltd
SHE:300577
|
China | CN¥3.58 Billion |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728
|
China | CN¥480.81 Million |
|
Latitude Group Holdings Ltd
AU:LFS
|
Australia | AU$6.92 Billion |
|
Neogen Chemicals Limited
NSE:NEOGEN
|
India | Rs-8.16 Billion |
|
REVO INSURANCE SPA O.N.
F:H0O
|
Germany | €351.39 Million |
|
Once Upon a Farm, PBC
NYSE:OFRM
|
USA | $240.49 Million |
|
Hubei Biocause Heilen Pharmaceutical Co. Ltd.
SHE:301211
|
China | CN¥117.63 Million |
|
Community West Bancshares
NASDAQ:CWBC
|
USA | $4.43 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Aura Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See AURA net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aura Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aura Biosciences Inc (2019–2025)
The table below shows the annual total liabilities of Aura Biosciences Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $32.52 Million | +6.50% |
| 2024-12-31 | $30.53 Million | +4.47% |
| 2023-12-31 | $29.23 Million | +3.09% |
| 2022-12-31 | $28.35 Million | +267.49% |
| 2021-12-31 | $7.71 Million | +181.47% |
| 2020-12-31 | $2.74 Million | -56.44% |
| 2019-12-31 | $6.29 Million | -- |
About Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the … Read more